Literature DB >> 2116311

The effects of felodipine in angina pectoris.

A R Lorimer1, P MacFarlane, S Pringle, M P Barbour, Y Fox, T D Lawrie.   

Abstract

The clinical response to felodipine, in addition to a beta-blocker, was evaluated and compared with placebo in this double-blind cross-over study. Twenty patients with exertional angina pectoris completed the study. Felodipine reduced the number of angina attacks and the Glyceryl Trinitrate (GTN) consumption. The median exercise capacity was increased 33% after 4 weeks' felodipine treatment compared with placebo. At maximal exercise, systolic blood pressure and rate pressure product were reduced by felodipine while no change was seen in heart rate or ST-depression. Felodipine reduced both supine and erect blood pressure. The mean supine blood pressure at rest was 138/82 mm Hg after four weeks' placebo treatment compared with 114/71 mmHg after felodipine 5-10 mg b.i.d. Felodipine has overall a modest but significant anti-anginal benefit when combined with a beta-blocker.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2116311     DOI: 10.1007/bf02336676

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  15 in total

1.  Antihypertensive efficacy of the calcium-antagonist felodipine in patients with persisting hypertension on beta-adrenoceptor blocker therapy. The Canadian Felodipine Study Group.

Authors: 
Journal:  Br J Clin Pharmacol       Date:  1988-11       Impact factor: 4.335

Review 2.  Coronary vascular responses to vasodilator drugs.

Authors:  R E Goldstein
Journal:  Prog Cardiovasc Dis       Date:  1982 May-Jun       Impact factor: 8.194

3.  Haemodynamic and myocardial metabolic effects of captopril in chronic heart failure.

Authors:  K Chatterjee; J L Rouleau; W W Parmley
Journal:  Br Heart J       Date:  1982-03

4.  Alterations in left ventricular function and coronary hemodynamics with captopril, hydralazine and prazosin in chronic ischemic heart failure: a comparative study.

Authors:  J L Rouleau; K Chatterjee; W Benge; W W Parmley; B Hiramatsu
Journal:  Circulation       Date:  1982-04       Impact factor: 29.690

5.  Effects of felodipine on haemodynamics and exercise capacity in patients with angina pectoris.

Authors:  J V Sheridan; P Thomas; P A Routledge; D J Sheridan
Journal:  Br J Clin Pharmacol       Date:  1987-04       Impact factor: 4.335

6.  Clinical and hemodynamic effects of combined propranolol and nifedipine therapy versus propranolol alone in patients with angina pectoris.

Authors:  S Braun; R Terdiman; D Berenfeld; S Laniado
Journal:  Am Heart J       Date:  1985-03       Impact factor: 4.749

7.  Vascular selectivity of felodipine.

Authors:  B Ljung
Journal:  Drugs       Date:  1985       Impact factor: 9.546

8.  Beta-blockers versus diuretics in hypertensive men: main results from the HAPPHY trial.

Authors:  L Wilhelmsen; G Berglund; D Elmfeldt; T Fitzsimons; H Holzgreve; J Hosie; P E Hörnkvist; K Pennert; J Tuomilehto; H Wedel
Journal:  J Hypertens       Date:  1987-10       Impact factor: 4.844

9.  The effects of treatment with felodipine as a single agent in coronary artery disease.

Authors:  M J Metcalfe; N S Chan-Wah-Hak; K Jennings
Journal:  Br Heart J       Date:  1989-03

10.  Acute haemodynamic effects of felodipine during beta blockade in patients with coronary artery disease.

Authors:  W Culling; M S Ruttley; D J Sheridan
Journal:  Br Heart J       Date:  1984-10
View more
  1 in total

Review 1.  Felodipine. A review of the pharmacology and therapeutic use of the extended release formulation in cardiovascular disorders.

Authors:  P A Todd; D Faulds
Journal:  Drugs       Date:  1992-08       Impact factor: 9.546

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.